Close Menu

La Jolla Institute for Allergy and Immunology

A new preprint indicates that immunity to SARS-CoV-2 may last for years after infection, the New York Times reports.

In Genome Biology this week: graph mapping-based approach to find indels in ancient DNA, tool to analyze chromatin interaction data, and more.

In Cell this week: analysis of multisystem inflammatory syndrome in children with SARS-CoV-2, fecal transplants boost gut microbiome development in infants born by C-section, and more.

A new partnership and licensing agreement will help the research institute aggregate genotype and phenotype data for the NIH-funded PreCISE Network asthma program.

The researchers hope the datasets from their study can help to explain the effects of disease-associated variants on specific cell types of the immune system.

A La Jolla Institute for Allergy and Immunology-led team sequenced the transcriptomes of thousands of CD4+ T cells and compared their expression patterns.

The Human Immunome Program, which is part of the Human Vaccines Project, eventually plans to profile B-cell and T-cell receptors in more than 1,000 individuals.

The La Jolla Institute for Allergy and Immunology (LIAI) has joined the Sanford Consortium for Regenerative Medicine, a new facility in San Diego that is set to open in November and will focus on stem cell research.

LIAI is preparing to assemble a permanent staff to run the screening facility, which is expected to include a manager and two full-time technicians, as well as a center director.

If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.